Amgen Inc Stock Price, News & Analysis

Amgen (NASDAQ: AMGN) reported promising Phase 1b results from the CodeBreaK 101 study, showcasing a median progression-free survival (PFS) of 5.7 months in patients with KRAS G12C-mutated colorectal cancer. The combination of LUMAKRAS® (sotorasib) and Vectibix® (panitumumab) achieved a 30% confirmed objective response rate in heavily pre-treated patients. Among 40 participants, 92.5% experienced disease control, and tumor shrinkage was observed in 88%. The study emphasizes the need for effective treatments in this challenging patient population.

LUMAKRAS (sotorasib) demonstrates significant progress in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) according to results from the Phase 3 CodeBreaK 200 trial. At one year, 25% of patients on LUMAKRAS experienced progression-free survival (PFS) compared to 10% for docetaxel. Additionally, the objective response rate (ORR) was **28%** for LUMAKRAS versus **13%** for docetaxel. Fewer treatment-related adverse events were reported with LUMAKRAS, reinforcing its potential as a key treatment option. Amgen plans to submit these findings to global health authorities.

Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 2022 Global Healthcare Conference on Sept. 13, 2022, at 9:10 a.m. ET. CEO Robert A. Bradway will lead the discussion. The event will be webcasted live and accessible to the public. Recorded presentations and updates about Amgen can be found on their website under the Investors section. Amgen, a biotechnology leader since 1980, focuses on innovative therapeutics for serious illnesses, and is part of the Dow Jones Industrial Average and Nasdaq-100 index.

Amgen announced positive results from two Phase 3 studies of Otezla (apremilast) presented at the 31st EADV Congress. The SPROUT study showed significant efficacy in pediatric patients aged 6-17 with moderate to severe plaque psoriasis, achieving a 33.1% response compared to 11.5% for placebo at week 16 (P<0.0001). The DISCREET study demonstrated improvements in adult genital psoriasis, with 38.7% achieving a clear response versus 19.1% for placebo (P=0.0003). Adverse events were consistent with Otezla's established safety profile.

Amgen (NASDAQ:AMGN) will host a webcast for the investment community on Sept. 12, 2022, at 1:30 p.m. ET, during the European Society for Medical Oncology Annual Congress (ESMO). Dr. David M. Reese and Amgen's clinical team will discuss findings from the LUMAKRAS® (sotorasib) CodeBreaK 200 study in non-small cell lung cancer, as well as the Phase 1b expansion of LUMAKRAS with Vectibix® (panitumumab) in colorectal cancer. The webcast will be available to the media, investors, and the public, and archived for 90 days on Amgen's website.

Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference on September 8, 2022, at 9:45 a.m. ET. The presentation will feature David M. Reese, M.D. and Peter H. Griffith, executives of the company. A live webcast will be available to investors and the public, with archival access for 90 days. Amgen aims to improve health outcomes through innovative therapeutics, leveraging advanced human genetics. As a significant player in biotechnology, Amgen is included in the Dow Jones Industrial Average and Nasdaq-100 indices.

Amgen will present at Citi's 2022 Global Healthcare Conference on September 7, 2022, at 8:50 a.m. ET. David M. Reese, M.D., and Peter H. Griffith will represent the company. The presentation will be webcast live for the media, investors, and the public, with an archive available for at least 90 days post-event. Amgen is a biotechnology leader, focusing on innovative therapies and high unmet medical needs. The company is part of the Dow Jones Industrial Average and the Nasdaq-100 index, recognized for its workplace culture and sustainability efforts.

Amgen announced that LUMAKRAS (sotorasib) met its primary endpoint of progression-free survival in the Phase 3 CodeBreaK 200 trial, outperforming standard treatment with docetaxel in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study involved 345 patients who had previously undergone standard chemotherapy and checkpoint inhibitor therapy. Further data will be shared at an upcoming medical congress. LUMAKRAS is approved in over 44 global markets, addressing a critical need for effective treatments in this patient population.

Amgen (AMGN) announced promising results from the Phase 3 SPROUT trial for Otezla (apremilast) in children aged 6-17 with moderate to severe plaque psoriasis. The positive outcomes will be shared at the EADV conference in Milan, Italy, on Sept. 7-10, 2022. Additional results from the Phase 3 DISCREET study on genital psoriasis will also be presented. Further highlights include analyses on rocatinlimab for atopic dermatitis. Amgen emphasizes its commitment to addressing treatment gaps for patients with autoimmune skin diseases.